L. Wyatt

发表

High Doses of GM-CSF Inhibit Antibody Responses in Rectal Secretions and Diminish Modified Vaccinia Ankara/Simian Immunodeficiency Virus Vaccine Protection in TRIM5α-Restrictive Macaques

B. Moss, D. Montefiori, C. Labranche, 2016, The Journal of Immunology.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

B. Moss, D. Montefiori, R. Varadarajan, 2019, Nature Communications.

The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

B. Moss, L. Wyatt, K. Shinoda, 2010, Virology.

Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization

B. Moss, K. Irvine, L. Wyatt, 2009, Virology Journal.

RNA Polymerase Mutations Selected during Experimental Evolution Enhance Replication of a Hybrid Vaccinia Virus with an Intermediate Transcription Factor Subunit Replaced by the Myxoma Virus Ortholog

B. Moss, T. Senkevich, Carey A Stuart, 2018, Journal of Virology.

Preparation of Cell Cultures and Vaccinia Virus Stocks

P. Earl, B. Moss, Catherine A. Cotter, 2015, Current protocols in microbiology.

HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.

Bin Li, Michael Monsour, Michael G Hudgens, 2006, Virology.

Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs.

B. Li, B. Moss, D. Montefiori, 2005, Virology.

Overcoming Immunity to a Viral Vaccine by DNA Priming before Vector Boosting

B. Moss, G. Nabel, W. Kong, 2003, Journal of Virology.

DNA/MVA HIV-1/AIDS vaccine elicits long-lived vaccinia virus-specific immunity and confers protection against a lethal monkeypox challenge

P. Earl, B. Moss, P. Nigam, 2007, Virology.

Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA Vaccine

James G. Herndon, Silvija I. Staprans, David C. Montefiori, 2001, Science.

Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.

P. Earl, B. Moss, D. Montefiori, 2007, Virology.

Dose-response studies for the elicitation of CD8 T cells by a DNA vaccine, used alone or as the prime for a modified vaccinia Ankara boost.

B. Moss, H. Robinson, R. Amara, 2007, Vaccine.

Studies on in vitro expression and in vivo immunogenicity of a recombinant MVA HIV vaccine.

B. Moss, H. Robinson, R. Amara, 2006, Vaccine.

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.

W. Heneine, P. Earl, B. Moss, 2004, AIDS research and human retroviruses.

Antibody Profiling by Proteome Microarray Reveals the Immunogenicity of the Attenuated Smallpox Vaccine Modified Vaccinia Virus Ankara Is Comparable to That of Dryvax

P. Earl, B. Moss, F. Newman, 2007, Journal of Virology.

Protective Immunity in Macaques Vaccinated with a Modified Vaccinia Virus Ankara-Based Measles Virus Vaccine in the Presence of Passively Acquired Antibodies

B. Moss, G. van Amerongen, A. Osterhaus, 2000, Journal of Virology.

Cellular and growth-factor requirements for the replication of human herpesvirus 6 in primary lymphocyte cultures.

E. C. Schirmer, C. June, G. Katsafanas, 1990, Advances in experimental medicine and biology.

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

P. Earl, B. Moss, D. Montefiori, 2002, Vaccine.

Human herpesvirus 7: antigenic properties and prevalence in children and adults

N. Frenkel, N. Balachandran, W. Rodriguez, 1991, Journal of virology.

Isolation of a new herpesvirus from human CD4+ T cells.

E. C. Schirmer, R. Danovich, C. June, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Human herpesvirus 7 is a constitutive inhabitant of adult human saliva

N. Frenkel, L. Wyatt, 1992, Journal of virology.

Human herpesvirus-6 strain groups: a nomenclature

H. Agut, L. Montagnier, B. Chandran, 1993, Archives of Virology.

Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

B. Moss, S. Melamed, L. Wyatt, 2013, Vaccine.

SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells

B. Moss, A. Weisberg, Jorge D Mendez-Rios, 2019, PLoS pathogens.

Generation of Recombinant Vaccinia Viruses

P. Earl, B. Moss, L. Wyatt, 2017, Current protocols in protein science.

Generation of Recombinant Vaccinia Viruses

P. Earl, B. Moss, L. Wyatt, 2017, Current protocols in molecular biology.

Generation of Recombinant Vaccinia Viruses

P. Earl, B. Moss, L. Wyatt, 2015, Current protocols in microbiology.

Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza

B. Moss, B. Bender, L. Wyatt, 1996, Journal of virology.

A conserved poxvirus NlpC/P60 superfamily protein contributes to vaccinia virus virulence in mice but not to replication in cell culture.

E. Koonin, B. Moss, A. Weisberg, 2008, Virology.

Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus

P. Earl, B. Moss, L. Rhodes, 2008, Proceedings of the National Academy of Sciences.

Preparation of Cell Cultures and Vaccinia Virus Stocks

P. Earl, B. Moss, M. Carroll, 1998, Current protocols in molecular biology.

Elicitation of High-Frequency Cytotoxic T-Lymphocyte Responses against both Dominant and Subdominant Simian-Human Immunodeficiency Virus Epitopes by DNA Vaccination of Rhesus Monkeys

B. Moss, A. Craiu, J. Schmitz, 2001, Journal of Virology.

The juxtamembrane but not the carboxyl-terminal domain of the insulin receptor mediates insulin's metabolic functions in primary adipocytes and cultured hepatoma cells.

D. Leroith, Y. Zick, L. Wyatt, 2000, Journal of molecular endocrinology.

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine.

B. Moss, D. Montefiori, Tianwei Yu, 2007, Virology.

Variations in the replication and antigenic properties of human herpesvirus 6 strains.

N. Frenkel, N. Balachandran, L. Wyatt, 1990, The Journal of infectious diseases.

Identification of Poxvirus Genome Uncoating and DNA Replication Factors with Mutually Redundant Roles

B. Moss, S. Ganesan, Debasis Panda, 2018, Journal of Virology.

Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine.

P. Earl, B. Moss, D. Montefiori, 2006, Virology.

Generation of Recombinant Vaccinia Viruses

P. Earl, B. Moss, M. Carroll, 1998, Current protocols in molecular biology.

Replication-deficient vaccinia virus encoding bacteriophage T7 RNA polymerase for transient gene expression in mammalian cells.

B. Moss, S. Rozenblatt, L. Wyatt, 1995, Virology.

Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization

Kylie M. Quinn, B. Moss, A. Folgori, 2013, The Journal of Immunology.

Immunization Recombinant Adenoviral Vector Human-, Simian-, and Chimpanzee-derived T Cells following + Gag-specific Cd8 of Simian Immunodeficiency Virus Quality, Phenotype, and Protective Capacity Comparative Analysis of the Magnitude

A. Folgori, R. Koup, M. Roederer, 2022 .

Poxvirus decapping enzymes enhance virulence by preventing the accumulation of dsRNA and the induction of innate antiviral responses.

B. Moss, G. Katsafanas, L. Wyatt, 2015, Cell host & microbe.

Novel Nonreplicating Vaccinia Virus Vector Enhances Expression of Heterologous Genes and Suppresses Synthesis of Endogenous Viral Proteins

P. Earl, B. Moss, W. Xiao, 2017, mBio.

Signature for Long-Term Vaccine-Mediated Control of a Simian and Human Immunodeficiency Virus 89.6P Challenge: Stable Low-Breadth and Low-Frequency T-Cell Response Capable of Coproducing Gamma Interferon and Interleukin-2

B. Moss, D. Montefiori, S. Staprans, 2005, Journal of Virology.

Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge.

P. Earl, B. Moss, D. Montefiori, 2003, AIDS research and human retroviruses.

Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge

B. Moss, J. Schmitz, M. Kuroda, 2000, Journal of Virology.

Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox

P. Earl, B. Moss, P. Jahrling, 2004, Nature.

Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

P. Earl, B. Moss, L. Eller, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses

J. Berzofsky, P. Earl, B. Moss, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells

B. Moss, A. Weisberg, M. Lal-Nag, 2020, PLoS pathogens.

Seroepidemiology of human herpesvirus 7 in healthy children and adults in Japan

T. Yoshikawa, N. Frenkel, L. Wyatt, 1993, Journal of medical virology.

HHV-6 and HHV-7 as exogenous agents in human lymphocytes.

N. Frenkel, L. Wyatt, 1992, Developments in biological standardization.

Evaluation of recombinant vaccinia virus--measles vaccines in infant rhesus macaques with preexisting measles antibody.

B. Moss, W. Bellini, P. Rota, 2000, Virology.

Preclinical Studies of Human Immunodeficiency Virus/AIDS Vaccines: Inverse Correlation between Avidity of Anti-Env Antibodies and Peak Postchallenge Viremia

B. Moss, D. Montefiori, H. Robinson, 2009, Journal of Virology.

Elucidating and Minimizing the Loss by Recombinant Vaccinia Virus of Human Immunodeficiency Virus Gene Expression Resulting from Spontaneous Mutations and Positive Selection

P. Earl, B. Moss, J. Vogt, 2009, Journal of Virology.

The D10 Decapping Enzyme of Vaccinia Virus Contributes to Decay of Cellular and Viral mRNAs and to Virulence in Mice

B. Moss, M. Orandle, L. Wyatt, 2013, Journal of Virology.

Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV

B. Moss, D. Venzon, Charles R. Brown, 2000, Journal of Virology.

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

W. Blattner, B. Moss, D. Montefiori, 2011, The Journal of infectious diseases.

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

J. Berzofsky, P. Earl, B. Moss, 2008, Virology.

Novel Modified Vaccinia Virus Ankara Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses

B. Moss, R. Amara, L. Wyatt, 2018, Journal of Virology.

Preparation of Cell Cultures and Vaccinia Virus Stocks

P. Earl, B. Moss, Catherine A. Cotter, 1998, Current protocols in molecular biology.

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

P. Earl, B. Moss, J. Vogt, 2008, Vaccine.

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.

P. Earl, B. Moss, D. Montefiori, 2004, AIDS research and human retroviruses.

DNA Vaccine–Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination

J. Mullins, P. Earl, B. Moss, 2018, Human gene therapy.

Critical Role for Env as well as Gag-Pol in Control of a Simian-Human Immunodeficiency Virus 89.6P Challenge by a DNA Prime/Recombinant Modified Vaccinia Virus Ankara Vaccine

P. Earl, B. Moss, D. Montefiori, 2002, Journal of Virology.

A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques

B. Moss, D. Montefiori, R. Varadarajan, 2017, Journal of Virology.

Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein

J. Berzofsky, P. Earl, B. Moss, 1998, Journal of Virology.

Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines

P. Earl, B. Moss, D. Montefiori, 2002, Journal of Virology.

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.

Todd M. Allen, J. Malley, P. Earl, 2002, Virology.

Elicitation of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Mucosal Compartments of Rhesus Monkeys by Systemic Vaccination

B. Moss, J. Mascola, M. Kuroda, 2002, Journal of Virology.

Differentiation between two distinct classes of viruses now classified as human herpesvirus 6.

E. C. Schirmer, K. Yamanishi, N. Frenkel, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology.

B. Moss, A. Osterhaus, G. van Amerongen, 2004, Vaccine.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

B. Moss, D. Montefiori, R. Varadarajan, 2019, Nature Communications.

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine

B. Haynes, B. Moss, D. Montefiori, 2017, Journal of Virology.

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.

B. Moss, D. Montefiori, H. McClure, 2004, AIDS research and human retroviruses.

Reduction of Simian-Human Immunodeficiency Virus 89.6P Viremia in Rhesus Monkeys by Recombinant Modified Vaccinia Virus Ankara Vaccination

B. Moss, D. Montefiori, J. Schmitz, 2001, Journal of Virology.

Preparation of Cell Cultures and Vaccinia Virus Stocks.

P. Earl, B. Moss, Catherine A. Cotter, 2017, Current protocols in protein science.

In vitro activation of human herpesviruses 6 and 7 from latency.

E. C. Schirmer, G. Katsafanas, N. Frenkel, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Control of a Mucosal Challenge and Prevention of AIDS in Rhesus Macaques by a Multiprotein DNA/MVA Vaccine

P. Earl, B. Moss, D. Montefiori, 2001 .

Prior Vaccination Increases the Epitopic Breadth of the Cytotoxic T-Lymphocyte Response That Evolves in Rhesus Monkeys following a Simian-Human Immunodeficiency Virus Infection

Norman L. Letvin, Kristin Beaudry, Michelle A. Lifton, 2002, Journal of Virology.

Short Communication: Studies in Macaques on Cross-Clade T Cell Responses Elicited by a DNA/MVA AIDS Vaccine, Better Conservation of CD8 Than CD4 T Cell Responses

B. Moss, H. McClure, J. Herndon, 2005 .

Seroprevalence of human herpesvirus 7 in patients with Kawasaki disease.

J. Newburger, J. Burns, N. Frenkel, 1994, The Pediatric infectious disease journal.

Isolation of a new herpes-virus from human CD4+ T cells

E. C. Schirmer, R. Danovich, C. June, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques.

T. H. van der Kwast, B. Moss, T. Kwast, 2001, Vaccine.

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

B. Moss, B. Murphy, S. Whitehead, 1999, Vaccine.

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.

B. Moss, B. Murphy, L. Wyatt, 1996, Vaccine.

A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus.

B. Moss, J. Bennink, G. Sutter, 1994, Vaccine.

T cell responses to respiratory syncytial virus fusion and attachment proteins in human peripheral blood mononuclear cells.

B. Moss, A. Osterhaus, G. Sutter, 2006, Viral immunology.

Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge.

B. Moss, R. Chanock, C. Lai, 2000, Vaccine.

Studies in macaques on cross-clade T cell responses elicited by a DNA/MVA AIDS vaccine, better conservation of CD8 than CD4 T cell responses.

B. Moss, H. McClure, J. Herndon, 2005, AIDS research and human retroviruses.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge

B. Moss, D. Montefiori, R. Varadarajan, 2019, Nature Communications.

Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer.

B. Moss, J. Schmitz, M. Kuroda, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Spontaneous and Targeted Mutations in the Decapping Enzyme Enhance Replication of Modified Vaccinia Virus Ankara (MVA) in Monkey Cells

B. Moss, N. Erez, W. Xiao, 2021, Journal of virology.

Preparation of cell cultures and vaccinia virus stocks.

P. Earl, B. Moss, M. Carroll, 2001, Current protocols in protein science.

The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.

B. Moss, B. Murphy, A. Durbin, 1998, Vaccine.

Bone marrow transplant recipients harbor the B variant of human herpesvirus 6.

T. Yoshikawa, G. Katsafanas, N. Frenkel, 1994, Bone marrow transplantation.